



### **EXAMPLE INSTRUCTIONS ONLY**

# ROUND-SPECIFIC INSTRUCTIONS WILL BE PROVIDED AFTER REGISTERING TO A ROUND

## Instructions for performing the EuroFlow MM MRD EQA round

#### FCS files and patient data:

- 1: Male, 65y, End of treatment
- 2: Male, 60y, CR, +9 months post-transplant
- 3: Female, 50y, D+100 post-transplant
- 4: Female, 70y, D+100 post-transplant

#### **Evaluation/panel used:**

All FCS data files were generated following the EuroFlow-NGF approach for sample processing, staining, and acquisition. You are provided with 2 FCS files per sample (Tube 1 and Tube 2).

#### **General instructions:**

- 1. All major cell populations in the samples should be identified and reported in the online data report form on https://ega.eslho.org/.
- 2. Estimation of lower limit of detection and lower limit of quantitation will follow previously published recomendations<sup>1,2</sup>, i.e., 20 dots and 50 dots, respectively, using total nucleated cells as denominator.

### Data reporting and conclusions:

Once the analysis is concluded, all data and general conclusions must be reported and submitted using the online report form before the deadline.

#### **Recommended references:**

- 1. Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, García-Sánchez O, Böttcher S, et al Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017 Oct;31(10):2094-2103.
- 2. Arroz M, Came N, Lin P, Chen W, Yuan C, Lagoo A, et al. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin Cytom. 2016;90(1):31-9.